about
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell linesProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaPrevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaClinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Investigation of Human Cancers for Retrovirus by Low-Stringency Target Enrichment and High-Throughput SequencingAge cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyPrognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium ProgramMYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrMicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphomaCancer stem cells and the cellular hierarchy in haematological malignancies.RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.Human papillomavirus infects placental trophoblast and Hofbauer cells, but appears not to play a causal role in miscarriage and preterm labor.Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma.Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue.A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technologyMicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic indexImmunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesPD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Prog
P50
Q27853399-B5CD8993-9C54-47A6-AA85-FA4E2967A61FQ28477988-AB55CB9D-51F8-48C5-96F0-48BF90F6A6A7Q28537857-05675EFA-EE15-4BB2-B628-BB5AEE99CABBQ33583294-C9D5CB42-09B2-472A-B86D-6594FF40F621Q33634415-2C765C5A-5E44-44C9-B5BF-3EE480299844Q34467490-8205ED1A-FDC2-48D1-8EF5-3617F0CA964BQ34543066-6B3F18CA-7CB3-4903-BD26-BEE34B70B19BQ35080097-00D65097-209F-4604-99ED-881A88D5F797Q35742364-46F2F9E3-EC33-4DAB-93C0-8C8A9879104FQ35742367-2BE32D7F-D416-4428-AFB9-B9A08F02C562Q35749247-A4847CD9-F8E0-4A51-AE67-467703DBFE45Q35987244-4B4B7907-F062-41B0-83EE-C39BE613589DQ36395599-C67B2686-417C-4849-93AF-B11BADB8BB16Q36414139-D42748F8-32DD-4210-AEB4-66711DE7BEDFQ36681461-DBC262A5-290A-4111-928D-EF03B9488B63Q36889725-EE6351D6-3B12-444F-A6ED-15F03F084C36Q37006876-EC9373A3-BE19-4920-B9BC-57087CE8A652Q37186470-467B94E5-F68C-45F6-BF0F-4E526677013AQ37602302-5668172F-F29C-458C-A634-02EA56A1EA08Q37610194-45351FD2-4D9B-4BD8-9ECF-B0BEE25DF4EDQ37635027-C829536A-A894-467C-813D-C25965626804Q39111039-ABCFCED5-458B-41E8-8A6E-963C0A5774ACQ39653218-D29D2B45-2137-40C9-9A28-C4834DC60B0DQ40138715-24C6312A-922F-4307-95D5-3DF8FF2C5465Q40454267-37EEDDF1-2778-497E-8A25-9F3C80127533Q42230312-A6094C55-967A-4E2D-82E4-120851718B6CQ42747897-1D0D130E-B4AC-4D9B-8552-13F93E1926B3Q42810702-3E41CAF0-127C-461E-90A1-6DDFF85FD1CFQ45358673-C7387A48-A308-44F5-AEBD-1C36A96BB7E2Q45991296-6C60BE8E-7E4E-44AE-B9A8-C74E840227BBQ48108703-6404C620-2183-44A8-A2D4-CDBE852DC1B6Q48614611-EC050D40-14AD-4B57-B9E0-F09191E00631Q50982468-C64B4890-4E21-46A4-A97C-0DD5A7C7F721Q51005409-A4372A9E-ABB4-4ACA-95E2-349A19D35985Q53098372-2C63DFC9-9E86-4EA0-B117-3524AC6985E4Q55068347-66A9A7D1-1BD8-4200-85AC-064628E1A18BQ89393373-5BF813E9-F77D-41EA-810F-3A16B51477BDQ90464161-E55C7104-70EE-4586-8A55-20FDCA93D208Q90880637-AECF4221-8302-4FC3-B2ED-A6E01632FAA7Q91148601-E501B1D7-84F9-4B24-8584-7E88297DAB71
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Karen Dybkaer
@ast
Karen Dybkaer
@en
Karen Dybkaer
@es
Karen Dybkaer
@nl
Karen Dybkaer
@sl
type
label
Karen Dybkaer
@ast
Karen Dybkaer
@en
Karen Dybkaer
@es
Karen Dybkaer
@nl
Karen Dybkaer
@sl
prefLabel
Karen Dybkaer
@ast
Karen Dybkaer
@en
Karen Dybkaer
@es
Karen Dybkaer
@nl
Karen Dybkaer
@sl
P106
P1153
6603389391
P21
P31
P496
0000-0003-2488-435X